Vir Biotechnology, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

23 Feb 2026

VIR

10-K: Vir Bio Forges Key Oncology, HDV Partnerships; Reports 2025 Financials

Vir Biotechnology strengthens its pipeline with a global strategic collaboration for prostate cancer candidate VIR-5500 and an exclusive commercial license for its chronic hepatitis delta treatment in Europe, Australia, and New Zealand, while reporting a net loss of $438.0 million for 2025.

NASDAQ

27 Feb 2025

VIR

Vir Biotechnology, INC

10-K: Vir Biotechnology Reports Full Year 2024 Results, Highlights Progress in Hepatitis and Oncology Programs

Vir Biotechnology advances its pipeline, focusing on hepatitis delta and oncology, while managing financial realignment and leadership changes.

NASDAQ

26 Feb 2024

VIR

Vir Biotechnology, INC

10-K: Vir Biotechnology 2023 Annual Report: Focus on Pipeline Advancement and Strategic Realignment

Vir Biotechnology's 2023 annual report highlights a year of strategic realignment, pipeline advancement, and continued focus on developing treatments for serious infectious diseases.